Cellectis (CLLS) Total Debt (QoQ) (2016 - 2026)
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn |
| 10 | Cellectis | 20.83 Bn | 20.62 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -9.55% |
| Dec 31, 2025 | 3.47% |
| Sep 30, 2025 | 10.19% |
| Jun 30, 2025 | 9.23% |
| Mar 31, 2025 | 1.20% |
| Dec 31, 2024 | 0.14% |
| Sep 30, 2024 | 5.45% |
| Jun 30, 2024 | -6.38% |
| Mar 31, 2024 | 24.59% |
| Dec 31, 2023 | 12.64% |
| Sep 30, 2023 | 6.27% |
| Jun 30, 2023 | 83.19% |
| Sep 30, 2022 | -6.93% |
| Sep 30, 2021 | -3.02% |
| Dec 31, 2020 | -8.38% |
| Sep 30, 2020 | 202.13% |
| Dec 31, 2018 | 177.98% |
| Sep 30, 2018 | -51.55% |
| Jun 30, 2018 | 189.05% |
| Mar 31, 2018 | 920.59% |
| Dec 31, 2017 | -26.09% |
| Sep 30, 2017 | -47.04% |
| Jun 30, 2017 | -79.62% |
| Mar 31, 2017 | -76.35% |
| Dec 31, 2016 | -17.59% |
| Sep 30, 2016 | -12.47% |